Aster DM Quality Care Limited has announced its unaudited financial results for the first quarter ended 30 June 2026. The company reported a profit of ₹10.89 crore for the period. This disclosure includes both standalone and consolidated financial performance, providing investors with key insights into the company’s operational and financial standing for the quarter.
Aster DM Quality Care Announces Q1 FY27 Financial Results
Aster DM Quality Care Limited has officially released its unaudited financial results for the quarter that concluded on 30 June 2026. The announcement details the company’s performance on both a standalone and consolidated basis, offering a comprehensive view of its financial health during the period.
Key Financial Highlights
For the quarter ended 30 June 2026, Aster DM Quality Care reported a profit before tax of ₹10.89 crore. The company’s revenue from operations stood at ₹725.73 crore on a standalone basis. Following tax expenses, the profit for the period was ₹25.19 crore. The total comprehensive income for the period was ₹28.34 crore.
Consolidated Performance
On a consolidated basis, the company’s revenue from operations for the quarter was ₹1,310.68 crore. The profit for the period for the owners of the company was ₹16.06 crore, contributing to a total comprehensive income of ₹16.16 crore. The consolidated profit before tax was ₹78.08 crore, with total tax expenses amounting to ₹48.80 crore.
Operational Overview
The unaudited standalone financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors on 5 August 2026. The company’s board meeting commenced at 11:30 AM IST and concluded at 04:40 PM IST. The financial statements have been prepared in accordance with Indian Accounting Standard 34 ‘Interim Financial Reporting’.
Merger and Acquisitions Impact
During the quarter, the company incurred expenses of ₹109.79 crore towards professional fees and other merger-related costs, presented as exceptional items in the standalone results. The company also noted an additional investment of ₹31.40 crore in its subsidiary, Malabar Institute of Medical Sciences Limited, increasing its shareholding to 81.29%. An investment of ₹45.09 crore was made in Aster DM-Super Specialty Hospital (Sarjapur) Private Limited, and ₹25.00 crore was invested in Optionally Convertible Redeemable Preference Shares (OCRPS) of Alfaone Medicals Private Limited.
Auditor’s Review
The unaudited financial results have undergone a limited review by Deloitte Haskins & Sells, the statutory auditors, who have expressed an unmodified conclusion on the financial statements.
Source: BSE
